 "Dr Reddy's")
Dr Reddy’s has gained about 10 per cent from February lows on expectations that some recovery in the US market and its emerging markets (EMs) focus should improve its growth trajectory.
The company’s performance during the December quarter showed some green shoots, with a 4 per cent sequential growth in the US.
Analysts believe its US generics business might be finally turning the corner. A few approvals for launches and positive developments on opioid drug Suboxone litigation also bode well, while some relief on regulatory front provides more confidence. The clearance of Duvvada facility by the US drug regulator was
